Aclaris Therapeutics Announces Pricing of $50.0 Million Offering of Common Stock and Pre-Funded Warrants

Impact · against what's priced in

Aclaris Therapeutics is facing immediate equity dilution following the pricing of a $50 million offering of common stock and pre-funded warrants. While the cash infusion extends the operational runway into 2027, the issuance of over 14 million potential new shares creates a net negative impact on current shareholders.

ACRS−0.20

No priced-in read yet